BIIB vs JAZZ: fair value comparison
Biogen Inc. and Jazz Pharmaceuticals plc · Updated 2026-08-31
Both currently screen as fairly valued on TickrTrends' Forward Fair Value model. Within Healthcare, BIIB currently sits closer to the top of our discount ranking.
| BIIB | JAZZ | |
|---|---|---|
| Verdict | Fairly valued | Fairly valued |
| Last price | $218.50 | $251.58 |
| 12-month range | $139.63–$202.95 | $129.66–$251.58 |
| Sector rank | #83 of 113 Healthcare | #84 of 113 Healthcare |
| Quality grade | B | B |
| Momentum grade | A | A |
| Leverage | Low | Moderate |
| Margin trend | Stable | Stable |
| Revenue growth | Modest | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | Uptrend |
| DCF cross-check | Undervalued | Fairly Valued |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: BIIB fair value analysis · JAZZ fair value analysis